Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug (markedsmisbrugsforordningen), følger hermed indberetning af ledende...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the...
-
08 February 2024 ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the...
-
Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives...
-
ALK’s near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative. Today, ALK announces that its near-term carbon reduction...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør årsrapport for 2023 torsdag den 8. februar 2024 om eftermiddagen. ALK afholder samme dag kl. 16.00 (CET) en telekonference for investorer og...
-
On Thursday, 8 February 2024 in the afternoon, ALK (ALKB:DC / OMX: ALK B / AKBLF) releases its annual report for 2023. ALK will host an online meeting for analysts and institutional investors...
-
ALK (ALKB:DC / OMX: ALK B / AKBLF) meddelte i dag, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn er accepteret til vurdering af de...